29th Apr 2016 09:11
LONDON (Alliance News) - GlaxoSmithKline PLC Friday said, in a joint statement with Save the Children, that an antiseptic gel developed by the two has been granted a positive scientific opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
The gel is for the treatment of newborn umbilical cord infections, intended for use in developing countries.
Glaxo will next submit local regulatory applications for the gel in low-income countries, and if approved, it will offer the gel at a not-for-profit price.
"By combining our development and manufacturing expertise, in both pharmaceuticals and consumer health, with Save the Children's on-the-ground knowledge of local healthcare systems and communities, we have developed a simple gel to help protect vulnerable newborns from infection," said President of Pharmaceuticals Research and Development Patrick Vallance in a statement.
Shares in Glaxo were down 0.7% at 1,478.00 pence Friday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline